Certified by Founder Lodge
Illimis Therapeutics
Korea, Republic Of - Seoul
START UP
1 Disclosed Funding Rounds $42,000,000
0 Participating Investments
-
Founded date
2021
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiate
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| July, 15 ,2025 | Series B | $42,000,000 |
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Franzy | $2,200,000 | (Jul 16, 2025)
Heka Global | $14,000,000 | (Jul 16, 2025)
Trupeer.ai | $3,000,000 | (Jul 16, 2025)
Fellow | $24,000,000 | (Jul 16, 2025)
Crash Override | $28,000,000 | (Jul 16, 2025)
